Source:http://linkedlifedata.com/resource/pubmed/id/19425079
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2009-8-3
|
| pubmed:abstractText |
Switching from oral medications to continuous infusion of levodopa/carbidopa gel reduces motor complications in advanced Parkinson's disease (PD), but effects on nonmotor symptoms (NMSs) are unknown. In this prospective open-label observational study, we report the effects of intrajejunal levodopa/carbidopa gel infusion on NMS in PD based on standard assessments utilizing the nonmotor symptoms scale (NMSS) along with the unified Parkinson's disease rating scale (UPDRS 3 motor and 4 complications) and quality of life (QoL) using the Parkinson's disease questionnaire (PDQ-8). Twenty-two advanced PD patients (mean age 58.6 years, duration of disease 15.3 years) were followed for 6 months. A statistically significant beneficial effect was shown in six of the nine domains of the NMSS: cardiovascular, sleep/fatigue, attention/memory, gastrointestinal, urinary, and miscellaneous (including pain and dribbling) and for the total score of this scale (NMSST) paralleling improvement of motor symptoms (UPDRS 3 motor and 4 complications in "best on" state) and dyskinesias/motor fluctuations. In addition, significant improvements were found using the Parkinson's disease sleep scale (PDSS) and the PDQ-8 (QoL). The improvement in PDQ-8 scores correlated highly significantly with the changes in NMSST, whereas a moderately strong correlation was observed with UPDRS changes. This is the first demonstration that a levodopa-based continuous dopaminergic stimulation is beneficial for NMS and health-related quality of life in PD in addition to the reduction of motor fluctuations and dyskinesias.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1531-8257
|
| pubmed:author |
pubmed-author:AntoniniAngeloA,
pubmed-author:CanesiMargheritaM,
pubmed-author:ChaudhuriK RayKR,
pubmed-author:FayeGuy CGC,
pubmed-author:ForgacsIanI,
pubmed-author:FoxKarenK,
pubmed-author:FoxThomasT,
pubmed-author:HonigHolgerH,
pubmed-author:ManciniFrancescaF,
pubmed-author:Martinez-MartinPabloP,
pubmed-author:OdinPerP
|
| pubmed:copyrightInfo |
Copyright 2009 Movement Disorder Society.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
30
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1468-74
|
| pubmed:meshHeading |
pubmed-meshheading:19425079-Aged,
pubmed-meshheading:19425079-Antiparkinson Agents,
pubmed-meshheading:19425079-Disability Evaluation,
pubmed-meshheading:19425079-Duodenum,
pubmed-meshheading:19425079-Endoscopes, Gastrointestinal,
pubmed-meshheading:19425079-Female,
pubmed-meshheading:19425079-Humans,
pubmed-meshheading:19425079-International Cooperation,
pubmed-meshheading:19425079-Levodopa,
pubmed-meshheading:19425079-Male,
pubmed-meshheading:19425079-Middle Aged,
pubmed-meshheading:19425079-Parkinson Disease,
pubmed-meshheading:19425079-Pilot Projects,
pubmed-meshheading:19425079-Prospective Studies,
pubmed-meshheading:19425079-Quality of Life,
pubmed-meshheading:19425079-Questionnaires,
pubmed-meshheading:19425079-Severity of Illness Index,
pubmed-meshheading:19425079-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
|
| pubmed:affiliation |
Department of Neurology, Central Hospital, Bremerhaven, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|